Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

OPX Biotechnologies

Request full access

At OPXBIO, we’re in the Good Chemistry business. We develop and produce bio-based chemicals and fuels that deliver more sustainable value to our customers

United StatesFounded 2007Energy

About OPX Biotechnologies

OPX Biotechnologies (OPXBIO), founded in 2007, operated in the renewable chemicals sector, focusing on producing bio-based chemicals and fuels as sustainable alternatives to petroleum-based products. The company was co-founded by Ryan T. Gill, a professor in Chemical and Biological Engineering at the University of Colorado Boulder whose research focuses on metabolic engineering and synthetic biology. This academic foundation was central to OPXBIO's core competency.

The company's business model revolved around leveraging its proprietary EDGE™ (Efficiency Directed Genome Engineering) technology. This platform was designed for the rapid optimization of microbes and bioprocesses, enabling the company to develop and scale products faster than conventional methods. OPXBIO's primary clients were large chemical companies seeking to integrate renewable materials into their existing supply chains. Its main product was BioAcrylic, a bio-based acrylic acid produced via fermentation of sugars. This product was developed as a direct, performance-equivalent replacement for petro-acrylic, which is used in a multi-billion dollar global market for applications like paints, adhesives, diapers, and detergents. Another key development was a process to produce fatty acids from syngas or sugar feedstocks, which could be converted into renewable chemicals and fuels like diesel and jet fuel.

A significant milestone was a joint development agreement with The Dow Chemical Company to scale up the BioAcrylic production process. The company also received a $6 million award from the U.S. Department of Energy's ARPA-E program to support its fatty acid research. After raising significant venture capital from investors including Mohr Davidow Ventures, US Renewables Group, and Braemar Energy Ventures, OPX Biotechnologies demonstrated its BioAcrylic production at a large, 3,000-liter demonstration scale. The company's trajectory culminated in April 2015, when its fermentation-based processes and systems were acquired by agricultural giant Cargill. The acquisition was seen as a strategic move for Cargill to expand its presence in commercial fermentation products for non-food applications. Following a transition period, OPX Biotechnologies was wound down.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2007
Headquarters
United States
Employees
11
Open positions
None listed
Dealroom signal
56.9/100
Industry
Energy
Sector
Energy, Developer Tools, Biotechnology, Producer, Hard Tech
Business model
Manufacturing
Client focus
B2C

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Apr 2015 $0 — Cargill —
SERIES COther financing Jul 2011 $37M $146M Braemar Energy Ventures · Mohr Davidow Ventures · US Renewables Group · Xseed Capital —
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

OPX Biotechnologies website traffic

Latest recorded traffic for OPX Biotechnologies is 290 monthly website visits. OPX Biotechnologies's team grew 0% over the past year.

Latest monthly visits290 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

OPX Biotechnologies in its local ecosystem

Live from Dealroom

The OPX Biotechnologies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • Xseed Capital
  • ARPA-E

Series A3 investors entered at this stage

  • Mohr Davidow Ventures
  • Braemar Energy Ventures
  • Altira

Series B and later2 investors entered at this stage

  • US Renewables Group
  • DBL Partners

Other known investors1 additional known investor

  • Cargill
Team profiled 14 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about OPX Biotechnologies on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See OPX Biotechnologies’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.